FeesSafety
Pluang+

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Company Fundamentals
20 Nov 2026, 20:00 WIB
Johnson & Johnson
View Source
Bullish
TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind using MRI to confirm axial inflammation, showed guselkumab reduced inflammation in sacroiliac joints more than twice as much as placebo at 24 weeks. These results highlight guselkumab's potential to address the complex symptoms of axial PsA, a condition affecting about 27% of PsA patients and causing debilitating back pain and stiffness. The safety profile was consistent with previous studies, supporting guselkumab as a promising treatment option for this underserved patient group.

Johnson & Johnson's stock is currently trading at USD 269.68 on Pluang, showing a 0.95% increase as of Nov 20, 2026 20:02 WIB. The company has a market cap of $643.09 billion and a dividend yield of 2.01%, reflecting steady investor interest alongside the positive clinical data.

More News (JNJ)

5 reliable dividend stocks keep raising payouts yearly for steady passive income growth.

5 reliable dividend stocks keep raising payouts yearly for steady passive income growth.

This article highlights five U.S.-listed companies—Johnson & Johnson, Procter & Gamble, Coca-Cola, Automatic Data Processing, and Lowe's—that have a strong track record of increasing dividends annually. These companies maintain dividend safety by pay...

Market News
Bullish
5 hours ago
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
13 hours ago
Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.

Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.

Johnson & Johnson's investigational prostate cancer drug JNJ-6143 demonstrated a 75% overall response rate in a Phase 1 trial involving patients with advanced metastatic castration-resistant prostate cancer. This promising early result highlights the...

Market News
Bullish
18 hours ago
3 Dow Dividend Stocks with Long Histories Offer Reliable Retirement Income

3 Dow Dividend Stocks with Long Histories Offer Reliable Retirement Income

Coca-Cola, Johnson & Johnson, and JPMorgan Chase are highlighted as strong Dow dividend stocks ideal for retirement income due to their long track records and diverse business models. Johnson & Johnson leads with 64 consecutive years of dividend incr...

Market News
Bullish
21 hours ago
Invest in Coca-Cola, Johnson & Johnson, and JPMorgan for reliable retirement dividends from diverse sectors.

Invest in Coca-Cola, Johnson & Johnson, and JPMorgan for reliable retirement dividends from diverse sectors.

Coca-Cola, Johnson & Johnson, and JPMorgan Chase are highlighted as strong Dow Jones dividend stocks for reliable retirement income. Each company has a long history of dividend payments, with Johnson & Johnson boasting 64 consecutive years of increas...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App